People

Rosemary G. Reilly

Partner

Reilly, Rosemary G.

Rosemary Reilly is a seasoned corporate lawyer with more than 20 years of experience advising life sciences and technology companies on corporate and securities matters. She provides ongoing counsel for clients ranging from startups and emerging companies to mature public companies, investment banks and venture capital firms. Drawing on her experience as in-house counsel, she has a unique understanding of the legal and business challenges faced by her clients.

In addition to advising clients on a wide range of corporate and securities matters, Ms. Reilly has significant experience with private and public securities offerings, mergers and acquisitions, joint ventures, strategic alliances, venture capital and strategic financings, and SEC compliance. She regularly advises boards in connection with securities transactions and general corporate matters, and provides advice on governance and commercial transactions.

Ms. Reilly also counsels emerging companies throughout their lifecycle and through complex transactions, including venture capital financings, initial public offerings and acquisitions. Learn more about Ms. Reilly's practice and how she can support your startup on WilmerHaleLaunch.com.

Prior to joining the firm, Ms. Reilly practiced in the Palo Alto, California office of a prominent international firm and previously in New York, New York, where she began her career as an associate. Her approach to legal advice is informed by her experiences dealing first-hand with the consequences that legal decisions can have on a company's bottom line. Specifically, she worked at two technology companies in Northern California: as general counsel at private technology company Shoreline Communications, Inc. (now Shortel, Inc.), and later in the legal department of NASDAQ-traded company Wind River Systems, Inc.

Recent Highlights

Ms. Reilly represents private companies in various stages of development, publicly traded companies, and venture capital firms with particular focus on the biotechnology, pharmaceutical and life sciences sectors. The clients she represents include Catabasis Pharmaceuticals, Inc., Editas Medicine, Inc., Innocrin Pharmaceuticals Holdings, LLC, Kadant Inc., Mitobridge, Inc., MKS Instruments, Inc., Stealth BioSciences, Inc., TransMedics Inc. and Viamet Pharmaceuticals Holdings, Inc.

Ms. Reilly's recent highlights include representing:

  • numerous companies in venture capital and private financings including Daktari Diagnostics, Editas Medicine, Innocrin, Mitobridge, TransMedics and Viamet Pharmaceuticals;
  • venture capital firms and strategic investors including Flagship Ventures and MPM Capital;
  • Catabasis Pharmaceuticals, Editas Medicine and Epizyme, Inc. in their initial public offerings; and
  • CoStim Pharmaceuticals in its acquisition by Novartis.

Professional Activities

Ms. Reilly is a frequent speaker on topics relating to corporate and securities transactions.

She is a member of the American Bar Association, the Massachusetts Bar Association and the Boston Bar Association. Ms. Reilly is also a member of the firm's Women's Leadership Initiative and Hiring Committee and is chair of the firm's Boston Senior Associates Committee.

Honors & Awards

  • Recommended in the 2017 edition of The Legal 500 United States for her capital markets: equity offerings practice
  • Awarded one of five Finance and Transactional Impact Cases of the Year by LMG Life Sciences for counseling Editas Medicine in its licensing and collaboration with Allergan

Publications & News

View

December 11, 2017

WilmerHale Represents Editas Medicine in $50M Offering of Common Stock

Editas Medicine, Inc., a leading genome editing company, announced the pricing of an underwritten offering of 1,970,000 shares of its common stock.

September 19, 2017

LMG Life Sciences Names WilmerHale Life Cycle Firm of the Year and Lisa Pirozzolo General Patent Litigator of the Year

Lawyers from across the United States and Canada gathered on September 13 at the Essex House in New York to celebrate the annual LMG Life Sciences Awards, recognizing the 2017 top firms and legal professionals in the life science industry.

July 7, 2017

MKS Instruments Successfully Completes Third Repricing of Secured Term Loan

On July 6, 2017, MKS Instruments, Inc., a global provider of technologies that enable advanced processes and improve productivity, announced the third successful repricing of its existing secured term loan.

March 16, 2017

Allergan and Editas Medicine Enter Into Strategic R&D Alliance

The agreement covers early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine's unparalleled CRISPR genome editing platform.

December 23, 2016

WilmerHale Reps Editas Medicine in Licensing of New Technologies

Editas Medicine, Inc., a leading genome editing company, announced it has exclusively licensed intellectual property related to new CRISPR technologies for human therapeutics that will enhance and broaden the range of medicines the company can develop.

October 6, 2016

WilmerHale Advises Catabasis Pharmaceuticals in Closing of $11.5M Offering of Common Stock

The WilmerHale deal team was led by Partner Rosemary Reilly and included Counsel Jeffries Oliver-Li, Associate Timothy Kulis, and Attorney Heidi Treiber.

June 3, 2016

WilmerHale Counsels TransMedics in Closing of $51.2M Growth Financing to Transform Organ Transplant Therapy

TransMedics, Inc., a medical technology company dedicated to improving quality, assessing viability and increasing the utilization of donor organs for transplantation announced the closing of $51.2 million growth equity financing.

February 3, 2016

WilmerHale Reps Editas Medicine in $94.4 Million IPO

WilmerHale represented Massachusetts-based gene editing company Editas Medicine in its $94.4 million initial public offering, which occurred on February 2, 2016.

September 5, 2012

SEC Proposes Rules to Eliminate the Prohibition Against General Solicitation and General Advertising for Rule 506 and Rule 144A Offerings

As mandated by the Jumpstart Our Business Startups Act, on August 29, 2012, the SEC proposed amendments to Rule 506 of Regulation D and to Rule 144A promulgated under the Securities Act of 1933, as amended, to eliminate the current prohibitions against general solicitation and general advertising in certain unregistered securities offerings.

March 27, 2012

Congress Passes New Capital Formation Legislation

Speaking Engagements

Practices

Skip Navigation Links.

Education

JD, Columbia Law School, 1994, Harlan Fiske Stone Scholar

BA, with high honors, Wesleyan University, 1989

Bar Admissions

Massachusetts

New York

California

Skip Navigation Links.